Evidence map›Paper›PMID 41743462›Full record

ReviewClinical ophthalmology (Auckland, N.Z.)2026

Overview of Intracameral Drug Delivery Systems in Glaucoma.

Kelvin S Y Shi, Yazan Abubaker, Mary V Lang, Raziye Dönmez Gün, Raphael G Banoub, Abhimanyu S Ahuja, Isabella V Wagner, Syril K Dorairaj

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kelvin S Y ShiDepartment of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA.ORCID 0009-0004-0870-2901
Yazan AbubakerDepartment of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA.ORCID 0009-0001-1688-0685
Mary V LangDepartment of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-0895-0903
Raziye Dönmez GünDepartment of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA.
Raphael G BanoubDepartment of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA.
Abhimanyu S AhujaDepartment of Ophthalmology, Casey Eye Institute, Portland, OR, USA.ORCID 0000-0003-4333-9189
Isabella V WagnerDepartment of Medicine, University of Florida College of Medicine, Gainesville, FL, USA.ORCID 0000-0001-5386-3692
Syril K DorairajDepartment of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glaucoma is the leading cause of irreversible blindness worldwide, and intraocular pressure (IOP) remains the only proven modifiable risk factor for slowing disease progression. Although topical medications are the standard first-line therapy, their effectiveness is limited by poor adherence and low ocular bioavailability. These limitations have prompted the development of non-topical drug delivery systems (DDSs) that aim to provide consistent long-term IOP control without reliance on patient-administered drops. Among these approaches, intracameral DDSs have received increasing attention for their ability to deliver medication directly to the anterior chamber. This review aims to provide clinicians with an overview of the design, clinical performance, and key considerations of the two FDA-approved intracameral implants, Durysta

Indexed as

drug deliveryglaucomaintracameralmedical devices

Identifiers

PMID41743462
PMCPMC12931133

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.